This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ImmunoGen, Inc. Announces Fifth New License Agreement In 2013

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics, today announced that Novartis has licensed the exclusive right to use the Company's antibody-drug conjugate (ADC) technology to develop anticancer therapeutics to an undisclosed target. This is the third license to be taken by Novartis – and the fifth to be taken by a major healthcare company – this year.

“In the past year, Novartis, Eli Lilly and Amgen have each licensed exclusive rights to use our industry-leading ADC technology for one or more targets,” commented Daniel Junius, President and CEO. “There are now numerous highly promising product candidates in the clinic through our own programs and through our partnerships, with many earlier-stage compounds advancing behind these.”

The terms of this third Novartis license are consistent with the license announced last month.

About ImmunoGen, Inc.

ImmunoGen develops targeted anticancer compounds with its well-tested ADC technology, which uses a tumor-targeting antibody to deliver one of the Company’s proprietary cancer-cell killing agents specifically to tumor cells. The most advanced compound with ImmunoGen’s ADC technology is Roche’s Kadcyla ®, which is marketed in the US by Genentech and is also gaining approvals internationally. Consistent with several ImmunoGen and partner compounds, Kadcyla utilizes ImmunoGen’s thioether (SMCC) linker and DM1 cytotoxic agent; ImmunoGen manufactured Kadcyla for non-pivotal clinical testing and developed the pivotal manufacturing process on behalf of Genentech. More information about ImmunoGen can be found at www.immunogen.com.

Kadcyla ® is a registered trademark of Genentech, Inc., a member of the Roche Group.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs